Search the Archive

Medicine: Skin Cancer Treatment #967311

NBC Evening News for Saturday, Jun 05, 2010
View other clips in this broadcast →

Material supplied by VTNA may be used for educational analysis or research only. Any editing, reproduction, publication, rebroadcast, public showing or public display may be prohibited by copyright laws. For any such use, please visit NBC NEWS Archives XPRESS.

(Studio: Lester Holt) The announcement of a new treatment for melanoma skin cancer reported; skin cancer statistics cited.

(New York: Robert Bazell) This new skin cancer treatment examined; details given about how Ipilimumab {IPI} stimulates the immune system & the drawbacks with the therapy. [Patient Rick WILKEY†† & WIFE - comment on his treatment.] [Angeles Clinic & Research Inst.'s Dr. Stephen O'DAY††- says melanoma is a deadly disease so this treatment in exciting.] How Bristol Myers Squibb is seeking FDA approval of this drug & access through a trial discussed.

Holt, Lester;
Bazell, Robert

Note to sponsor members: The Vanderbilt Television News Archive video player requires a modern operating system and browser to work properly. If you are experiencing playback problems, check the minimum requirements and adjust your setup accordingly. After adjustments, if you continue to experience problems, please contact us.

Welcome! Above is the abstract of the item that you're interested in viewing from the Vanderbilt Television News Archive's collection. You have three options if you'd like to view this item:

  • You may request a loan of this video by registering on our website and placing an order.
  • You may visit the Television News Archive on the Vanderbilt campus to view on-site from the Archive's collection.
  • If you are associated with a college or university, you may ask your library if they would like to become a sponsor, which would give students and faculty at your institution the ability to view items from our collection.

If you believe that you are associated with a sponsoring college or university and have received this message in error, please let us know.